Passion to deliver our commitments

Tc–99m - TroDAT-1

The First Commercialized Tc99m labeled radiopharmaceutical for imaging of Dopamine transporter

Parkinson's disease (PD) is a common progressive neurological disorder that results from degeneration of nerve cells in a region of the brain that controls movement. The recent development of tracers for positron emission tomography (PET) and single photon emission computed tomography (SPECT), in conjunction with dedicated imaging devices, provides valuable tools for in vivo diagnosis and treatment of PD and related neurodegenerative diseases.

Tc-99m-TRODAT-1, which binds to the dopamine transporter (DAT) located on the presynaptic nerve endings in striatum, has been reported by Dr. Hank F. Kung as a SPECT imaging compound for diagnosing and monitoring the treatment of Parkinson's disease patients.

TRODAT-1 kit, all-in-one kit formulation for the preparation of Tc-99m-TRODAT-1, is the second radiopharmaceutical being commercialized as imaging dopamine transporter in the world. With the extensive availability of Tc99m and ability to stock the cold kits, it is generally accepted that Tc-99m-TRODAT-1 will be.